Home » Myriad Completes Acquisition of Sividon Diagnostics
Myriad Completes Acquisition of Sividon Diagnostics
June 3, 2016
Myriad Genetics has finalized its acquisition of Sividon Diagnostics, a breast cancer prognostic company, for approximately $39 million upfront.
Under the deal, Myriad will also gain $17 million in potential milestones. — Anisa Jibrell
Upcoming Events
-
21Oct